A detailed history of Alps Advisors Inc transactions in Erasca, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 202,715 shares of ERAS stock, worth $496,651. This represents 0.0% of its overall portfolio holdings.

Number of Shares
202,715
Holding current value
$496,651
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.79 - $2.63 $362,859 - $533,140
202,715 New
202,715 $478,000
Q3 2022

Nov 14, 2022

SELL
$5.82 - $10.68 $32,720 - $60,042
-5,622 Reduced 7.78%
66,663 $520,000
Q2 2022

Aug 11, 2022

BUY
$4.58 - $8.72 $331,065 - $630,325
72,285 New
72,285 $403,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $299M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.